Stevenage Bioscience Catalyst leads with first digital kiosk in the UK from Merck

Pictured L-R: James Latham, Development and Leasing Director at SBC and Dr George Tetley, Co-founder at ImmTune Therapies

  • The first digital kiosk to be installed in the UK is in use at Stevenage Bioscience Catalyst (SBC) powered by the Merck M Lab™ Collaboration Center
  • The new technology enables SBC occupiers to explore solutions to their processing challenges.

STEVENAGE 26 th October 2022: Brand new technology has been installed in Stevenage Bioscience Catalyst’s (SBC’s) Community Lab for occupiers to use. The UK’s first digital kiosk powered by the Merck M Lab Collaboration Center is designed to:

  • enable occupiers to engage virtually or in-person with scientists and engineers who understand biological processes
  • optimise and scale up processes for small or large therapeutic molecules and
  • learn best practices for moving from good laboratory practices to good manufacturing practices.

Dr Sally Ann Forsyth OBE, CEO of SBC, said, “The new digital kiosk is now available to the 45+ companies in the SBC community. We are delighted to provide access at no charge to this exciting new technology to help our occupiers to develop and commercialise cutting-edge therapeutics.”

Sven Verguts, PhD, Collaboration Consultant for Emerging Biotech at Merck said, “At Merck we understand the power of collaboration. Ecosystems, like the one cultivated by SBC, are a veritable breeding ground for innovative biotech projects, which Merck is eager to support by sharing its resources and expertise. In an effort to bring those resources to innovators with a convenient on-demand access point, we have developed a new tool in the shape of an interactive digital kiosk. These kiosks will be premiered at SBC in the UK and also made available at innovation hotspots worldwide. Here they will allow innovators to discover Merck’s capabilities from their own campus, at their own pace, to get the support they require when they need it the most.”

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is a world-leading science park of global significance and located at the centre of the largest cluster of cell and gene therapy companies in Europe. It provides a supportive environment to help companies grow by providing access to specialist equipment, mentoring and finance suited to their stage of development. Since its opening in 2012, occupier companies have secured £2.9bn in finance making the cluster one of the most attractive for investment in biotechnology in the UK.

About Merck’s M Lab™ Collaboration Centers

Merck’s M Lab™ Collaboration Centers are your resource for designing smart solutions. Our global network of scientific experts, innovative technologies, and flexible non-GMP facilities allow you to explore novel modalities or test drive advanced techniques without disrupting your own operations. Our facilities are the key to helping you bring life-enhancing therapeutics to more patients, more efficiently, with more confidence. 

For more information:

Stevenage Bioscience Catalyst 


M Lab™ Collaboration Centers

Click here to learn more about M Lab™ Collaboration Centers.


Merck tools, services and digital platforms empower scientists and engineers at every stage, helping deliver breakthrough therapies faster. Learn more about us today.